Obesity & Cardiovascular Health: Blood Pressure, Cholesterol & SELECT

Weight loss reliably improves cardiovascular risk factors — blood pressure, cholesterol, blood sugar and inflammation. Whether it reduces actual events (heart attacks, strokes, deaths) depends on how it's achieved. Semaglutide reduced major cardiovascular events by about 20% in the SELECT trial, the strongest evidence that a weight-loss medication can lower events, not just the scale.

The central distinction: risk factors are not events

This page turns on one idea, and most confusion about "weight loss and the heart" dissolves once it's clear:

"Losing weight" improves risk factors — the measurable markers that predict cardiovascular disease: blood pressure, LDL and triglycerides, blood glucose, inflammation, and the workload on the heart.
"Reducing cardiovascular events" means fewer actual outcomes — heart attacks, strokes, cardiovascular deaths, heart-failure hospitalisations.

These are related but not the same thing, and history is full of interventions that improved a risk factor without reducing events (or even caused harm). So we hold weight-loss treatments to the higher standard where the evidence exists: did it move the outcomes, not just the numbers? → The W8Experts Clinical Approach

Why the distinction matters: a treatment can lower your blood pressure or weight and still need separate proof that it prevents heart attacks. When that proof exists, we say so; when it doesn't yet, we say that too.

How obesity injures the cardiovascular system

Excess and dysfunctional adiposity affects the heart and vessels through many linked pathways:

Hypertension — more body mass, activation of the sympathetic and renin–angiotensin systems, and sodium handling raise blood pressure; weight loss lowers it, often substantially. Grade A 🟢
Dyslipidaemia — obesity typically raises triglycerides and lowers HDL, with a shift toward small, atherogenic LDL particles. Grade A 🟢 → Nutrition
Coronary artery disease — the combined risk-factor burden accelerates atherosclerosis and raises heart-attack risk. Grade A 🟢
Heart failure — obesity is a major driver of heart failure, particularly the "preserved ejection fraction" (HFpEF) type, through pressure and volume load, inflammation and fat around the heart. Grade A 🟢
Atrial fibrillation — obesity, sleep apnea and atrial stretch raise AFib risk; weight loss reduces AFib burden in studies. Grade B 🟡
Stroke — via hypertension, AFib, diabetes and atherosclerosis. Grade A 🟢

Much of this risk clusters as metabolic syndrome and overlaps with fatty liver, where cardiovascular disease — not liver disease — is actually the leading cause of death. → MASLD & Cardiovascular Risk · Obesity & Diabetes

What weight loss does to the risk factors

Here the evidence is consistent and encouraging. Even 5–10% sustained weight loss meaningfully improves blood pressure, triglycerides, HDL, glucose and inflammatory markers, and larger sustained loss does more. Losing visceral and ectopic fat is especially valuable, because that is the metabolically active fat driving the risk. Grade A 🟢 → BMI, Body Fat & Body Composition

This is genuine benefit and reason enough to pursue healthy weight loss. But improving risk factors is the expected first step — the question patients and clinicians increasingly ask is whether a given treatment goes further and reduces events.

SELECT — the landmark event trial

The SELECT trial showed that a weight-loss medication can reduce cardiovascular events, not just risk factors.

Who: adults with established cardiovascular disease and overweight or obesity, without diabetes.
What: semaglutide 2.4 mg versus placebo, over roughly 3 years.
Result: about a 20% reduction in major adverse cardiovascular events (MACE) — a composite of cardiovascular death, non-fatal heart attack and non-fatal stroke (hazard ratio ~0.80). Grade A 🟢 → Semaglutide

This led to an FDA indication for cardiovascular risk reduction in that population. It matters because it clears the higher bar: the benefit was measured in outcomes, in a population chosen for cardiovascular risk. Notably, the event reduction appeared larger than weight loss alone would predict, suggesting semaglutide's cardiovascular benefit isn't purely a weight effect — a reminder that "how" you lose weight can matter as much as "how much." → GLP-1 hub

Important boundaries: - SELECT studied people with established cardiovascular disease and without diabetes — it doesn't automatically generalise to everyone. - For tirzepatide, dedicated cardiovascular-outcome trials (SURMOUNT-MMO, SURPASS-CVOT) are maturing; there is no SELECT-equivalent outcomes claim yet, despite its greater average weight loss. Greater weight loss is promising but is not the same as proven event reduction. Grade B 🟡 → Tirzepatide

The other proven cardiovascular players

SGLT2 inhibitors reduce heart-failure hospitalisations and cardiovascular events (with kidney protection), in people with and without diabetes — a major tool where heart failure is the concern. Grade A 🟢 → Obesity & Diabetes
Bariatric/metabolic surgery is associated with lower cardiovascular events and mortality in large cohort studies, alongside its diabetes-remission benefit. Grade B 🟡 → Bariatric Surgery
Mediterranean dietary pattern has randomised evidence for reducing cardiovascular events — the strongest event-level evidence of any eating pattern. Grade A 🟢 → Nutrition
Cardiorespiratory fitness independently predicts survival; improving fitness helps the heart even when weight moves little. Grade A 🟢 → Exercise, Muscle & Body Composition

What the evidence says

What we know: obesity causes hypertension, dyslipidaemia, coronary disease, heart failure, AFib and stroke; weight loss improves the risk factors; semaglutide reduced cardiovascular events ~20% in SELECT (established CVD, no diabetes). Grade A 🟢
What we think: treating adiposity and its risk factors together — with agents that also reduce events where proven — offers better cardiovascular protection than treating weight alone. Grade B 🟡
What we don't know: whether tirzepatide reduces events (trials maturing), and the long-term cardiovascular effect of stopping therapy and regaining weight. Grade B 🟡 → Weight Regain & Maintenance
What patients should do: pursue sustained weight loss for risk-factor benefit, and where cardiovascular risk is high, prioritise treatments with proven event reduction; don't assume any weight loss automatically prevents heart attacks.

Questions patients ask about obesity & the heart — 20+ answered

(These questions form this page's FAQPage schema; the most common are surfaced in the disclosure block below.)

Does losing weight prevent heart attacks and strokes?

It reliably improves the risk factors that cause them, and some treatments — notably semaglutide in SELECT — have been proven to reduce actual events. But improving a number isn't automatic proof of fewer events; that depends on how the weight loss is achieved.